Remdesivir

COVID-19: Highly concentrated antibody solution not effective treatment - study

The trial, backed by Dr. Anthony Fauci's NIAID, tested the combination of anti-coronavirus hyperimmune intravenous immunoglobulin and remdesivir.

|ByAARON REICH
COVID-19 (illustrative)
A health worker holds up a vial of Imdevimab, an antibody cocktail designed to produce resistance to the coronavirus disease (COVID-19), at San Giuseppe Hospital, in Albano, Italy, April 22, 2021

‘Weeks, not months:’ Scientists develop ambitious pandemic response plan

Researchers believe that focusing on the drug cocktail strategy would reduce the burden on healthcare systems and help prevent disease spread.

|ByJERUSALEM POST STAFF
A logo is pictured on the World Health Organization (WHO) headquarters in Geneva, Switzerland.

WHO advises against Gilead's remdesivir for all hospitalized COVID-19 patients

It is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for COVID-19 in the summer after early trials showed some promise.

|ByREUTERS
A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.

Countries where remdesivir is approved or supported for treating COVID-19

On Thursday, the US Food and Drug Administration approved remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease.

|ByREUTERS

Gilead's coronavirus antiviral remdesivir gets conditional EU clearance

Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial.

JULY 4, 2020ByREUTERS
Vials of investigational coronavirus disease (COVID-19) treatment drug are capped at a facility.

Gilead prices COVID-19 drug remdesivir at $2,340 per patient

Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of COVID-19.

JUNE 30, 2020ByREUTERS
Vials of investigational coronavirus disease (COVID-19) treatment drug are capped at a facility.

Gilead to enroll pediatric patients for late-stage remdesivir study

The trial will assess the effectiveness and safety of the drug in the patients, which would include newborns to adolescents, across more than 30 sites in the United States and Europe.

JUNE 17, 2020ByREUTERS
Vials of investigational coronavirus disease (COVID-19) treatment drug are capped at a facility.